More knocks to the oxidation hypothesis for vascular disease?

Clinical Science

Volumn 116, Issue 1, 2009, Pages 41-43

  Mullan, Adam ^a   Sattar, Naveed ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Antioxidant; Apolipoprotein; Coronary heart disease; Isoprostane; Lipid

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; BETA CAROTENE; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; VITAMIN;

AMINO ACID BLOOD LEVEL; ANTIOXIDANT ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE MARKER; HUMAN; NOTE; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK REDUCTION; SOCIAL STATUS; VITAMIN SUPPLEMENTATION; DIET SUPPLEMENTATION; EVIDENCE BASED MEDICINE; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; TREATMENT FAILURE;

ANTIOXIDANTS; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; EVIDENCE-BASED MEDICINE; HUMANS; OXIDATION-REDUCTION; OXIDATIVE STRESS; TREATMENT FAILURE; VITAMINS;

EID: 60549112226     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20080486     Document Type: Note

References (12)

1. Bjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G. and Gluud, C. (2008) Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst. Rev. 2008, Issue 2. Art No.: CD007176, doi: 10.1002/14651858.CD007176
2. Bazzano, L. A., Reynolds, K., Holder, K. N. and He, J. (2006) Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA, J. Am. Med. Assoc. 296, 2720-2726
3. Ebbing, M., Bleie, O., Ueland, P. M. et al. (2008) Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA, J. Am. Med. Assoc. 300, 795-804
4. Lawlor, D. A., Davey, S. G., Kundu, D., Bruckdorfer, K. R. and Ebrahim, S. (2004) Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence? Lancet 363, 1724-1727
5. Tsimikas, S. (2008) In vivo markers of oxidative stress and therapeutic interventions. Am. J. Cardiol. 101, 34D-42D
6. Tsimikas, S., Willerson, J. T. and Ridker, P. M. (2006) C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J. Am. Coll. Cardiol. 47, C19-C31
7. Macdonald, D. L., Terry, T. L., Agellon, L. B., Nation, P. N. and Francis, G. A. (2003) Administration of tyrosyl radical-oxidized HDL inhibits the development of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 23, 1583-1588
8. Woodward, M., Croft, K. D., Mori, T. A. et al. (2009) Association between both lipid and protein oxidation and the risk of fatal or non-fatal coronary heart disease in a human population. Clin. Sci. 116, 53-60
9. Vassalle, C., Botto, N., Andreassi, M. G., Berti, S. and Biagini, A. (2003) Evidence for enhanced 8-isoprostane plasma levels, as index of oxidative stress in vivo, in patients with coronary artery disease. Coron. Artery Dis. 14, 213-218
10. Schwedhelm, E., Bartling, A., Lenzen, H. et al. (2004) Urinary 8-iso-prostaglandin F2α as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation 109, 843-848
11. Kiechl, S., Willeit, J., Mayr, M. et al. (2007) Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler. Thromb. Vasc. Biol. 27, 1788-1795
12. Tardif, J. C., McMurray, J. J., Klug, E. et al. (2008) Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet 371, 1761-1768